GeneDx Holdings (WGS) Azione Prezzo

GeneDx Holdings Corp. generates revenue through its GeneDx and Legacy Sema4 segments. The GeneDx segment offers pediatric and rare disease diagnostics, primarily utilizing whole exome and genome sequencing, along with data and information services. It provides genetic diagnostic tests, screening solutions, and information to clinicians and patients. The Legacy Sema4 segment delivers reproductive and women’s health diagnostics, as well as somatic oncology testing and screening products. Both segments target healthcare providers and institutions seeking personalized health insights for diagnosis, treatment planning, and drug discovery. The company’s products include genetic diagnostic tests, screening solutions, and information services under the GeneDx brand, while Legacy Sema4 focuses on reproductive health, women’s health, and oncology diagnostics. These services are sold to healthcare providers and institutions that require actionable health intelligence to inform clinical decisions and improve patient outcomes. The segments serve distinct medical specialties, with GeneDx emphasizing rare diseases and pediatric care, and Legacy Sema4 covering reproductive health and cancer diagnostics. Revenue is derived from diagnostic testing services provided through both segments. The GeneDx segment’s core offerings are whole exome and genome sequencing for rare and pediatric conditions, while Legacy Sema4 specializes in reproductive, women’s health, and somatic oncology testing. These services are delivered to healthcare systems and providers who integrate genetic data into patient care pathways for better diagnosis and treatment strategies.